Moreover, FOXP1 has been proposed as an adverse prognostic factor in intensively treated AML patients who received autologous stem cell transplant at remission; AML patients with elevated FOXP1 gene expression at diagnosis had a significantly shorter progression-free and overall survival after intensive induction chemotherapy and autoSCT [74]. This evidence concerns the gene FOXP1 and acute myeloid leukemia.